TUMOR-SPECIFIC CLAUDIN 18.2 ANTIBODIES
The invention provides tumor specific anti-CLDN18.2 antibodies or fragments thereof. The antibodies or fragments thereof exhibit increased binding to tumor tissue expressing CLDN 18.2 over healthy tissue expressing CLDN18.2. Further, the antibodies do not exhibit cross-reactivity to CLDN18.1. The in...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | BAMMERT, Lukas WALDMEIER, Lorenz HOSKOVA, Simona IVA, Valentova BEERLI, Roger MOEBIUS, Ulrich KYRYCH SADILKOVA, Lenka |
| description | The invention provides tumor specific anti-CLDN18.2 antibodies or fragments thereof. The antibodies or fragments thereof exhibit increased binding to tumor tissue expressing CLDN 18.2 over healthy tissue expressing CLDN18.2. Further, the antibodies do not exhibit cross-reactivity to CLDN18.1. The invention also provides nucleic acids, vectors, host cells and medical uses.
L'invention concerne des anticorps anti-CLDN18.2 spécifiques d'une tumeur ou des fragments de ceux-ci. Les anticorps ou fragments de ceux-ci présentent une liaison plus élevée au tissu tumoral exprimant CLDN 18,2 qu'au tissu sain exprimant CLDN 18.2. En outre, les anticorps ne présentent pas de réactivité croisée à CLDN 18.1. L'invention concerne également des acides nucléiques, des vecteurs, des cellules hôtes et des utilisations médicales. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2021130291A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2021130291A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2021130291A13</originalsourceid><addsrcrecordid>eNrjZFALCfX1D9INDnB19nTzdFZw9nEMdfH0UzC00DNScPQL8XTyd_F0DeZhYE1LzClO5YXS3AzKbq4hzh66qQX58anFBYnJqXmpJfHh_kYGRoaGxgZGloaOhsbEqQIAJl0j_A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>TUMOR-SPECIFIC CLAUDIN 18.2 ANTIBODIES</title><source>esp@cenet</source><creator>BAMMERT, Lukas ; WALDMEIER, Lorenz ; HOSKOVA, Simona ; IVA, Valentova ; BEERLI, Roger ; MOEBIUS, Ulrich ; KYRYCH SADILKOVA, Lenka</creator><creatorcontrib>BAMMERT, Lukas ; WALDMEIER, Lorenz ; HOSKOVA, Simona ; IVA, Valentova ; BEERLI, Roger ; MOEBIUS, Ulrich ; KYRYCH SADILKOVA, Lenka</creatorcontrib><description>The invention provides tumor specific anti-CLDN18.2 antibodies or fragments thereof. The antibodies or fragments thereof exhibit increased binding to tumor tissue expressing CLDN 18.2 over healthy tissue expressing CLDN18.2. Further, the antibodies do not exhibit cross-reactivity to CLDN18.1. The invention also provides nucleic acids, vectors, host cells and medical uses.
L'invention concerne des anticorps anti-CLDN18.2 spécifiques d'une tumeur ou des fragments de ceux-ci. Les anticorps ou fragments de ceux-ci présentent une liaison plus élevée au tissu tumoral exprimant CLDN 18,2 qu'au tissu sain exprimant CLDN 18.2. En outre, les anticorps ne présentent pas de réactivité croisée à CLDN 18.1. L'invention concerne également des acides nucléiques, des vecteurs, des cellules hôtes et des utilisations médicales.</description><language>eng ; fre</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2021</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210701&DB=EPODOC&CC=WO&NR=2021130291A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210701&DB=EPODOC&CC=WO&NR=2021130291A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>BAMMERT, Lukas</creatorcontrib><creatorcontrib>WALDMEIER, Lorenz</creatorcontrib><creatorcontrib>HOSKOVA, Simona</creatorcontrib><creatorcontrib>IVA, Valentova</creatorcontrib><creatorcontrib>BEERLI, Roger</creatorcontrib><creatorcontrib>MOEBIUS, Ulrich</creatorcontrib><creatorcontrib>KYRYCH SADILKOVA, Lenka</creatorcontrib><title>TUMOR-SPECIFIC CLAUDIN 18.2 ANTIBODIES</title><description>The invention provides tumor specific anti-CLDN18.2 antibodies or fragments thereof. The antibodies or fragments thereof exhibit increased binding to tumor tissue expressing CLDN 18.2 over healthy tissue expressing CLDN18.2. Further, the antibodies do not exhibit cross-reactivity to CLDN18.1. The invention also provides nucleic acids, vectors, host cells and medical uses.
L'invention concerne des anticorps anti-CLDN18.2 spécifiques d'une tumeur ou des fragments de ceux-ci. Les anticorps ou fragments de ceux-ci présentent une liaison plus élevée au tissu tumoral exprimant CLDN 18,2 qu'au tissu sain exprimant CLDN 18.2. En outre, les anticorps ne présentent pas de réactivité croisée à CLDN 18.1. L'invention concerne également des acides nucléiques, des vecteurs, des cellules hôtes et des utilisations médicales.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2021</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZFALCfX1D9INDnB19nTzdFZw9nEMdfH0UzC00DNScPQL8XTyd_F0DeZhYE1LzClO5YXS3AzKbq4hzh66qQX58anFBYnJqXmpJfHh_kYGRoaGxgZGloaOhsbEqQIAJl0j_A</recordid><startdate>20210701</startdate><enddate>20210701</enddate><creator>BAMMERT, Lukas</creator><creator>WALDMEIER, Lorenz</creator><creator>HOSKOVA, Simona</creator><creator>IVA, Valentova</creator><creator>BEERLI, Roger</creator><creator>MOEBIUS, Ulrich</creator><creator>KYRYCH SADILKOVA, Lenka</creator><scope>EVB</scope></search><sort><creationdate>20210701</creationdate><title>TUMOR-SPECIFIC CLAUDIN 18.2 ANTIBODIES</title><author>BAMMERT, Lukas ; WALDMEIER, Lorenz ; HOSKOVA, Simona ; IVA, Valentova ; BEERLI, Roger ; MOEBIUS, Ulrich ; KYRYCH SADILKOVA, Lenka</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2021130291A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2021</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>BAMMERT, Lukas</creatorcontrib><creatorcontrib>WALDMEIER, Lorenz</creatorcontrib><creatorcontrib>HOSKOVA, Simona</creatorcontrib><creatorcontrib>IVA, Valentova</creatorcontrib><creatorcontrib>BEERLI, Roger</creatorcontrib><creatorcontrib>MOEBIUS, Ulrich</creatorcontrib><creatorcontrib>KYRYCH SADILKOVA, Lenka</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>BAMMERT, Lukas</au><au>WALDMEIER, Lorenz</au><au>HOSKOVA, Simona</au><au>IVA, Valentova</au><au>BEERLI, Roger</au><au>MOEBIUS, Ulrich</au><au>KYRYCH SADILKOVA, Lenka</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>TUMOR-SPECIFIC CLAUDIN 18.2 ANTIBODIES</title><date>2021-07-01</date><risdate>2021</risdate><abstract>The invention provides tumor specific anti-CLDN18.2 antibodies or fragments thereof. The antibodies or fragments thereof exhibit increased binding to tumor tissue expressing CLDN 18.2 over healthy tissue expressing CLDN18.2. Further, the antibodies do not exhibit cross-reactivity to CLDN18.1. The invention also provides nucleic acids, vectors, host cells and medical uses.
L'invention concerne des anticorps anti-CLDN18.2 spécifiques d'une tumeur ou des fragments de ceux-ci. Les anticorps ou fragments de ceux-ci présentent une liaison plus élevée au tissu tumoral exprimant CLDN 18,2 qu'au tissu sain exprimant CLDN 18.2. En outre, les anticorps ne présentent pas de réactivité croisée à CLDN 18.1. L'invention concerne également des acides nucléiques, des vecteurs, des cellules hôtes et des utilisations médicales.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2021130291A1 |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | TUMOR-SPECIFIC CLAUDIN 18.2 ANTIBODIES |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T09%3A52%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=BAMMERT,%20Lukas&rft.date=2021-07-01&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2021130291A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |